A/Prof David Anderson

Deputy Director
Centre for Biomedical Research
Burnet Institute


Licensing opportunities

Burnet spinoff Nanjing BioPoint Diagnostics is interested in novel diagnostics for unmet medical needs especially using lateral flow immunochromatography, with R&D both at Burnet and in Nanjing to help convert promising assays from other formats such as ELISAs

Contract research opportunities

Development of point of care (lateral flow) diagnostics

Other opportunities

Joint venture or license development of diagnostics

Research Activities

Our major activities are in translational research in diagnostics:
(1) the development of rapid, point-of-care and/or laboratory-based assays for the diagnosis and management of infectious diseases including HIV, syphilis, hepatitis and liver disease, gut leakage and sepsis;
(2) commercial development of diagnostics through Burnet's spinoff company, Nanjing BioPoint Diagnostics (PR China), with ISO13485 (2016) certified manufacturing facilities in China, allowing production for registration and sale (eg CE mark for EU and other markets).


Assay development, validation and pilot manufacture for ELISA and rapid, point of care tests (including contract services)


Suzanne Crowe
Brendan Crabb
Greg Tannock, Burnet Institute
Alan Landay, Rush University, Chicago
Tom Denny, Duke University, Durham
Bill Heath, Axxin Ltd
A/Prof Rosemary Ffrench
Jack Richards
Mary Garcia
Roy Hall
Jody Peters

Other Lab Members

Mary Garcia
Huy Van
Fan Li

Research Images

Other members with similar research interests

prev next

Prof David Jans

Department of Biochemistry and Molecular Biology Monash University SEE FULL PROFILE >

Prof Bill Charman

Faculty of Pharmacy and Pharmaceutical Sciences Monash University SEE FULL PROFILE >

Prof Melanie Bahlo

Population Health and Immunity Walter and Eliza Hall Institute of Medical Research SEE FULL PROFILE >

Upcoming Events